Criteria | Total number of responses | Distribution of responses | ||
---|---|---|---|---|
 |  | Always | Sometimes Never | |
MCDA matrix criteria | Â | Â | Â | Â |
Quality of evidence | Â | Â | Â | Â |
Adherence to requirements of decision making body | 9 | 33 | 67 | 0 |
Completeness and consistency of reporting evidence | 9 | 89 | 11 | 0 |
Relevance and validity of evidence | 9 | 89 | 11 | 0 |
Disease impact | Â | Â | Â | Â |
Disease severity | 9 | 89 | 11 | 0 |
Size of population affected by disease | 9 | 67 | 33 | 0 |
Intervention | Â | Â | Â | Â |
Current clinical guidelines | 9 | 89 | 11 | 0 |
Current interventions limitations | 9 | 78 | 22 | 0 |
Improvement of efficacy/effectiveness | 9 | 89 | 11 | 0 |
Improvement of safety & tolerability | 9 | 78 | 22 | 0 |
Improvement of PRO, convenience & adherence | 9 | 44 | 56 | 0 |
Public health interest (prevention & risk reduction) | 9 | 78 | 22 | 0 |
Type of medical service | 9 | 89 | 11 | 0 |
Economics | Â | Â | Â | Â |
Budget impact on health plan | 9 | 100 | 0 | 0 |
Cost-effectiveness of intervention | 9 | 89 | 11 | 0 |
Impact on other spending | 9 | 78 | 22 | 0 |
Other criteria | Â | Â | Â | Â |
Appropriate use | 9 | 89 | 11 | 0 |
Opportunity costs | 9 | 78 | 22 | 0 |
Organizational structure | 9 | 22 | 78 | 0 |
Stakeholder pressures | 9 | 33 | 67 | 0 |
Political context | 9 | 11 | 89 | 0 |
Population priorities and access | 9 | 22 | 78 | 0 |
Regulatory status of intervention | 9 | 56 | 44 | 0 |